LOGIN  |  REGISTER

Exscientia (NASDAQ: EXAI) Stock Quote

Last Trade: US$4.84
Volume: 0
5-Day Change: 0%
YTD Change: 0%
Market Cap: US$633.170M

Latest News From Exscientia

Both programmes demonstrate Exscientia’s ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple... Read More
Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD biomarkers related to LSD1 inhibitor treatment OXFORD, England / Oct 09, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium... Read More
OXFORD, England / Aug 28, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company’s website,... Read More
Entered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial Phase I monotherapy data expected in 2H24 Launched AWS AI-powered platform to advance drug discovery LSD1 and MALT1 inhibitor programmes continue to progress towards the clinic, on track for 2H24 IND/CTA... Read More
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 OXFORD, England / Jul 18, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced it has reached an... Read More
State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost OXFORD, England / Jul 10, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud... Read More
AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia’s internal oncology pipeline OXFORD, England / Jun 06, 2024 / Business Wire / Exscientia plc... Read More
OXFORD, England / May 30, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England Goldman Sachs 45 th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 11, 2024 at... Read More
Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and... Read More
Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / May 14, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and... Read More
OXFORD, U.K. / Mar 21, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. “In 2023, we significantly expanded our technological capabilities with the opening of... Read More
Company to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT OXFORD, England / Mar 14, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a... Read More
OXFORD, England / Feb 28, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: TD Cowen 44 th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts Barclays 26 th Annual Global Healthcare Conference. Fireside chat on Tuesday, March... Read More
Multicentre EXCYTE-2 study to evaluate precision medicine platform in patients with acute myeloid leukaemia Supports ongoing development of LSD1 inhibitor (EXS74539) currently in preclinical development OXFORD, England / Feb 07, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship... Read More
Distinguished honour for Exscientia’s founder and Chief Executive Awarded in the 2024 New Year Honours List by HM King Charles III Follows multiple recent recognitions for outstanding personal achievements and those of Exscientia OXFORD, England / Jan 02, 2024 / Business Wire / Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the... Read More
$2.3 million grant expected to drive research to harness the host interferon response as a pathway to treating and preventing pandemic influenza OXFORD, England / Dec 05, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to... Read More
OXFORD, England / Nov 21, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at... Read More
OXFORD, U.K. / Nov 09, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST. “At Exscientia, we are laser-focused on building an engine that designs and develops high impact... Read More
Company to host conference call and webcast on November 9, 2023, at 1:30 p.m. GMT / 8:30 a.m. EST OXFORD, England / Nov 02, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business... Read More
Renowned technology champion to strengthen company’s development of precision medicine and clinical innovation platforms OXFORD, U.K. / Oct 17, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate... Read More
Demonstrated preclinical efficacy of LSD1 inhibitor in primary AML samples Initial data supporting combination potential of LSD1 inhibitor with AML standard of care therapies Tumour growth inhibition through MALT1 in monotherapy and combination while lowering bilirubin toxicity risk OXFORD, England / Oct 16, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming... Read More
Concentrating rapidly emerging pipeline on most differentiated, highest value oncology targets, including CDK7 and LSD1 programmes Partnering or discontinuing internal development of programmes outside of core focus, including A 2A and select discovery targets Strategy will support continued investment into market-leading technology while maintaining cash runway well into 2026 Partnered pipeline continues to progress with... Read More
Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales Up to $113 million of potential milestone payments in the discovery phase, with $20 million... Read More
OXFORD, England / Aug 31, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2023, at 3:45 p.m. EDT (8:45 p.m. BST) in Boston, Massachusetts Morgan Stanley Global Healthcare Conference 2023 . Formal presentation on... Read More
OXFORD, U.K. / Aug 10, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) - Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT. “In the first half of 2023, four molecules precision-designed by Exscientia advanced... Read More
Company to host conference call and webcast on August 10, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / Aug 03, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update... Read More
First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication Builds off of pioneering AI-guided functional precision medicine research in haematological cancers OXFORD, England & VIENNA, Austria / Jul 18, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian... Read More
Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index Preclinically discovered non-invasive PD biomarker to be confirmed alongside clinical trial OXFORD, England / Jul 10, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s... Read More
Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS617 treatment responders SAN FRANCISCO and SHANGHAI, China, July 10, 2023 (GLOBE NEWSWIRE) -- GT Apeiron , a biopharmaceutical company harnessing the... Read More
Expanded leadership structure maintains nimble technology development across multitude of discovery and development functions OXFORD, England / Jun 29, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative technologies to catalyse instrumental change in the way drug candidates are being discovered,... Read More
OXFORD, England / Jun 06, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at... Read More
OXFORD, England / May 24, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. “With our sixth AI-designed compound reaching the clinical development stage plus two more in active... Read More
Latest technology advances to innovate drug design, discovery and development Novel automated discovery laboratory on track to open in 2023 OXFORD, England / May 22, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition... Read More
Company to host conference call and webcast on May 24, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / May 17, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and... Read More
Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England / May 15, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective... Read More
Renowned thought leader in computational biology and data science for cancer research Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance OXFORD, England / May 03, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of... Read More
Includes recent advancements from precision designed compounds Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment OXFORD, England / Apr 19, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in... Read More
OXFORD, U.K. / Mar 23, 2023 / Business Wire / Recent developments in the Exscientia's (Nasdaq: EXAI) pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. "2022 was marked by significant milestones for Exscientia, including signing a groundbreaking... Read More
OXFORD, England / Mar 16, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by... Read More
OXFORD, England / Mar 15, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. These abstracts highlight the components of Exscientia's approach to precision discovery, design and... Read More
OXFORD, England / Mar 14, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds... Read More
OXFORD, England & BERLIN, Germany / Mar 07, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charité will evaluate the potential of Exscientia’s precision medicine platform to select better treatments and improve outcomes... Read More
OXFORD, England / Feb 22, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: Morgan Stanley EMEA HealthTech Conference. Management will participate in virtual investor meetings on Wednesday, March 1, 2023 Cowen 43 rd Annual Healthcare Conference . Formal presentation on Tuesday, March 7, 2023, at 11:10 a.m.... Read More
EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor Eligible for pre-commercial milestone payments and, if approved, tiered royalties on net product sales OXFORD, England / Feb 02, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that EXS4318... Read More